A Case Report of Adalimumab Successfully Treated a Severe Plaque Psoriasis Patient with Psoriatic End-Stage Renal Disease

Figures & data

Table 1 Laboratory Examination Pre-Biologic Treatment

Inspection Projects, Unit of Measure	Pre-Treatment with Biologics	Normal Range
CBC
WBC, 10^9/L	17.36	3.50~9.50
RBC, 10^12/L	2.98	4.30~5.80
Hb, g/L	87.0	130.0~175.0
NEUT, 10^9/L	12.78	1.80~6.30
NEUT%	83.2	40.0~75.0
LFT
TP, g/L	58	63~82
ALB, g/L	28	35~50
LDH, U/L	582	120~250
RFT
Urea, mmol/L	25.4	3.2~7.1
Cre, μmol/L	945	58~110
UA, μmol/L	848	208~506
eGFR, mL/(min×1.73m^2)	5.7	>90
TB-related
T-SPOT.TB	Negative	Negative
PPD test	Negative	Negative
Immune indexes
TNF-α, pg/mL	33.60	0~8.10
IL-1β, pg/mL	5.1	0~5.0
IL-2R, IU/mL	>7500	223.0~710.0
IL-6, pg/mL	119.0	0~3.4
IL-8, pg/mL	38.0	0~62.0
IL-10, pg/mL	5.3	0~9.1

Abbreviations: CBC, complete blood count; WBC, white blood cell; RBC, red blood cell; Hb, hemoglobin; NEUT, neutrocyte; LFT, Liver Function Test; TP, total protein; ALB, albumin; LDH, lactic dehydrogenase; RFT, Renal Function Test; Cre, creatinine; UA, uric acid; eGFR, estimated glomerular filtration rate; TB, tuberculosis; PPD, purified protein derivative; TNF, tumor necrosis factor; IL, interleukin.

Figure 1 Clinical manifestation of Psoriasis. (a) Skin involvement of more than 80% of the body surface area on admission. The Psoriasis Area and Severity Index (PASI) score was 62. (b) Skin involvement after two sessions of Adalimumab treatment. The PASI score was 12. (c) Skin involvement at 12 weeks after Adalimumab initiation. The PASI score was 1.